Workflow
Pharmacy Retail
icon
Search documents
CVS vs. Amazon: Healthcare Battle Continues- Which Stock to Buy Now?
ZACKS· 2025-06-30 20:01
Core Insights - Amazon's entry into healthcare has significantly disrupted the traditional pharmacy landscape, raising concerns for established players like CVS Health [1][3] - CVS Health is rebounding strongly in 2025, becoming one of the top performers in the S&P 500, with a focus on integrated care and leveraging its extensive physical presence [2][10] Group 1: Company Strategies - Amazon is leveraging its logistics capabilities and technology to redefine healthcare delivery, including AI-powered prescription fulfillment and at-home diagnostics [1][5][7] - CVS Health is capitalizing on its vast network of over 9,000 retail pharmacies and integrated services to provide coordinated care and improve patient outcomes [4][6] Group 2: Performance Metrics - CVS Health reported $95 billion in revenue in Q1 2025 and has achieved a year-to-date stock performance of 56%, ranking eighth in the S&P 500 [2][10] - In contrast, Amazon's stock has only risen by 1.8% year-to-date, placing it at number 262 in the S&P 500 rankings [10][9] Group 3: Financial Projections - The Zacks Consensus Estimate for CVS's 2025 earnings per share suggests a 12.7% improvement from 2024, indicating strong growth potential [12] - Amazon's 2025 EPS is projected to improve by 12.5% over the previous fiscal year, reflecting ongoing growth in its healthcare initiatives [14] Group 4: Valuation Comparisons - CVS is trading at a forward price-to-earnings ratio of 10.48X, which is above its five-year median, yet remains attractively valued compared to Amazon's 33.3X [15] - Amazon's current valuation is below its five-year median, suggesting potential for future growth but also indicating higher execution risk in its healthcare ventures [15][16]
Walgreens Outlook Improves As Buyout Faces Shareholder Vote Next Month
Forbes· 2025-06-26 21:30
Core Insights - Walgreens Boots Alliance reported a quarterly loss that was better than expected, with rising pharmacy sales indicating potential for financial recovery under new private equity ownership [2] - The acquisition by Sycamore Partners, valued at $10 billion, is anticipated to lead to significant cost-cutting measures [3] - Shareholder approval for the acquisition is scheduled for a special meeting on July 11, with no serious opposition reported [4] Financial Performance - In the fiscal third quarter, Walgreens reported a net loss of $175 million, or 20 cents per share, compared to a net income of $344 million, or 40 cents per share, in the same period last year [5] - Total sales increased by 7% to $39 billion in the third quarter [5] - The U.S. Healthcare segment generated $2.1 billion in sales, with an operating loss of $64 million, significantly improved from a $220 million loss in the previous year [6] Cash Flow and Cost Management - Analysts noted Walgreens' ability to generate positive free cash flow in the quarter, a significant improvement given recent negative trends [7] - The company is on track to meet its goal of closing 1,200 underperforming stores by fiscal 2027, having already closed over 400 stores in the first nine months of the fiscal year [8] Strategic Outlook - The transition to private ownership is viewed positively, allowing Walgreens to focus on long-term reinvention without the pressures of public market expectations [10] - The company aims to close 500 stores in the current fiscal year as part of its cost-saving initiatives [8]
Walgreens Sales Rise but CEO Says Turnaround Will ‘Take Time'
PYMNTS.com· 2025-06-26 18:23
Core Insights - Walgreens is experiencing an increase in sales as it prepares for a transition to private ownership, with a deal expected to close in the second half of 2025 for $10 billion [3]. Financial Performance - The company reported quarterly earnings showing sales of $39 billion, reflecting a 7.2% increase year-over-year, driven by growth in its U.S. retail pharmacy and international segments [2]. - The U.S. retail pharmacy segment achieved quarterly sales of $30.7 billion, up 7.8% year-over-year, with comparable sales increasing by 10.3%. Pharmacy sales specifically rose by 11.8% for the quarter [4]. - However, retail sales fell by 5.3%, attributed to weaker performance in grocery, household, health and wellness, and beauty categories [4]. Economic Context - The broader economic environment shows a contraction, with the economy shrinking by 0.5% in the first quarter, a downward revision from a previously estimated 0.2% dip [5]. - Consumer spending is declining, influenced by new tariffs, leading to changes in shopping behaviors among consumers [6][5]. Strategic Focus - The company is committed to a turnaround plan that emphasizes a disciplined approach to managing cash needs while investing in necessary adaptations to the evolving pharmacy and retail landscape [3].
Rite Aid Prepares to Sell Remaining Assets
PYMNTS.com· 2025-06-10 22:27
Core Insights - Rite Aid is nearing a June 18 deadline for bidding on its remaining assets, with potential buyers including Walgreens, Kourtney Kardashian, private equity firms, and brand management companies [1][3] - The company filed for bankruptcy in May, marking its second filing in three years, primarily due to high debt, inflationary pressures, and competition [4][5] Group 1: Bankruptcy and Asset Sale - Rite Aid operates 1,200 stores and has over $2 billion in debt, facing challenges from inflation and lower consumer demand [4][5] - A bankruptcy judge has approved store closures and the sale of customer prescription files to CVS Health, Walmart, and others [3] - Rite Aid is pursuing a strategic sale process for substantially all of its assets, with a focus on maximizing value [5] Group 2: Store Closures and Sales - The company has targeted 210 store closures, with 95 locations revealed on May 19 [6] - Agreements have been reached to sell prescription files for over 1,000 pharmacy locations, with CVS, Walgreens, and others as successful bidders [6][7] - CVS plans to purchase prescription files for 625 locations and take over 64 physical Rite Aid stores [7]
Kourtney Kardashian, Walgreens, more eyeing bankrupt Rite Aid's assets: report
New York Post· 2025-06-10 18:24
Core Insights - Rite Aid is undergoing bankruptcy proceedings, with various companies, including Walgreens and brand management firms, evaluating its remaining assets [1][4][9] - Kourtney Kardashian has shown interest in acquiring Rite Aid's Thrifty ice cream brand, which has a history dating back to 1940 [3][7] Group 1: Bankruptcy and Asset Evaluation - Rite Aid operates approximately 1,200 stores and serves around 8 million customers, having filed for bankruptcy for the second time in two years [4][8] - The bankruptcy judge has approved store closures and the sale of customer prescription files to 13 buyers, including CVS Health and Walgreens [4][10] - Brand management companies such as Authentic Brands Group, WHP Global, and Marquee Brands are assessing Rite Aid's intellectual property and loyalty program [1][2] Group 2: Interest in Thrifty Ice Cream Brand - Kourtney Kardashian, co-founder of Lemme and owner of Poosh, is interested in Rite Aid's Thrifty ice cream brand, which is sold at various retailers [3][5][6] - Thrifty ice cream has a notable history and has attracted interest from consumer-focused private equity firms as well [7]
Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share
Forbes· 2025-06-03 13:01
Core Insights - Amazon Pharmacy is launching new features aimed at attracting seniors covered by Medicare's drug benefit, a market currently dominated by CVS Health and Walgreens [2][4] - The new "caregiver support feature" allows customers to have someone else manage their medications, enhancing convenience for those caring for elderly family members [3][8] - Customers with Medicare Part D can access PillPack, which simplifies medication management through pre-sorted and labeled packets delivered to their homes [4][6] Market Context - The U.S. prescription market is largely controlled by CVS and Walgreens, which together hold a 40% market share, while Amazon's share is less than 1% [6] - CVS filled 435 million prescriptions in Q1, a 4.3% increase year-over-year, while Walgreens filled over 309 million prescriptions, up 3.4% [5] - Combined, CVS and Walgreens generated over $370 billion in prescription revenues last year [5] Demographic Trends - The Medicare prescription market is expanding, with over 11,000 Americans turning 65 every day, indicating a growing customer base for Amazon Pharmacy [6] - More than 50 million Americans are currently caring for an aging family member, presenting a significant opportunity for Amazon to cater to this demographic [7]
Walgreens Ups Use of Robotics With New Micro-Fulfillment Center
PYMNTS.com· 2025-05-20 16:54
Core Insights - Walgreens is increasing its investment in robotics with a new micro-fulfillment center in Minnesota, which will support nearly 200 locations and process approximately 13 million prescriptions annually [1][4] - The micro-fulfillment centers allow pharmacists to focus more on patient care rather than prescription filling, enhancing community health and patient experience [2][5] - The company operates a network of 12 micro-fulfillment centers that fulfill over 3.5 million prescriptions weekly, supporting more than 5,000 stores nationwide [3][4] Operational Efficiency - The micro-fulfillment centers have resulted in a 24% year-over-year increase in shipped volumes, with around 16 million prescriptions filled monthly [4][5] - In October 2023, these centers supported 4,300 locations, increasing to 4,800 by February 2024, handling 40% of the prescription volume at supported pharmacies [4][5] Industry Context - Other major retailers like Walmart and Amazon are also investing in robotics for fulfillment, with Amazon introducing a robot capable of sensing touch and Walmart utilizing robotic 3D printing technology for warehouse construction [6][7]
CVS Health Stock Rallies 38% in May: Is it a Buy Amid PBM Pressure?
ZACKS· 2025-05-14 20:01
Core Viewpoint - CVS Health shares have increased nearly 38% this month due to stronger-than-expected Q1 2025 results, despite concerns over store closures related to new PBM reform legislation [1][2] Financial Performance - CVS Health reported Q1 2025 adjusted EPS of $2.25 and adjusted operating income of $4.6 billion, exceeding market expectations [5] - The company raised its full-year adjusted EPS guidance to a range of $6 to $6.20, up from $5.75 to $6, reflecting confidence in operational strength across its core businesses [5] Management Changes - Brian Newman was appointed as CFO and Amy Compton-Phillips as CMO, positioning CVS to advance its long-term vision of becoming a trusted healthcare company [6] Digital Innovation - The CVS Health app is enhancing customer engagement by providing better visibility into care and real-time AI recommendations [7] Operational Efficiency - CVS Health is streamlining prior authorizations, with 95% of Aetna's requests processed within 24 hours, and is expanding its bundled cancer care model [8] - The pharmacy segment processes over 1.7 billion prescriptions annually, with strategic investments in technology driving performance [9] Affordability Initiatives - CVS is expanding access to therapies, partnering with Novo Nordisk to offer Wegovy at lower costs and leading the U.S. market with its low-cost Humira biosimilar, generating over $1 billion in savings for clients [10] Strategic Focus - CVS Health will exit the ACA individual exchange markets by 2026 due to losses, focusing instead on Medicare, commercial, and Medicaid plans [11] Regulatory Challenges - CVS is closing 23 pharmacies in Arkansas due to new legislation banning PBMs from owning pharmacies, which CVS argues will limit access and increase drug spending [12][14] Valuation Insights - CVS Health's forward P/E ratio is 9.46X, lower than the S&P 500's 21.37X, but higher than competitors Walgreens Boots and Herbalife [15][17] - The stock's premium may be justified by its scale and strategic focus on digital health and value-based care [17] Analyst Outlook - CVS Health is trading nearly 22% below its average price target according to 22 analysts, indicating strong upside potential [19] Investment Recommendation - Despite regulatory challenges, CVS Health remains a strong long-term investment due to its diversified business model and advancements in digital health [20]
Rite Aid Attributes Bankruptcy Return to Empty Shelves, Shopper Trade-Down
PYMNTS.com· 2025-05-06 23:57
Core Viewpoint - Rite Aid's inability to recover successfully and its return to bankruptcy protection is attributed to inventory shortages and changes in consumer behavior, particularly among lower-income shoppers [1][5]. Inventory Issues - The inventory problems arose from unexpected financial constraints, with Rite Aid planning to access approximately $166 million from credit facilities post-bankruptcy, but lenders delayed or withdrew commitments [2]. - Only one loan of $66.75 million was secured, described as insufficient and received too late to replenish inventory for the holiday shopping season [3]. Vendor Relations - Rite Aid's post-emergence business plan relied on vendors returning to less restrictive payment terms, but many vendors refused to ease terms [4]. Consumer Behavior - The company noted a shift in consumer behavior, with lower-income shoppers opting for household goods from more affordable retailers, impacting sales [5]. - Research indicates that during economic distress, a significant majority of shoppers alter their purchasing behaviors, with only 16% stating that inflation did not affect their consumption [6]. Importance of Stocking - Keeping non-pharmacy sections stocked is critical for customer retention, as many purchases are impulse-driven [7]. - The combined pressures from inventory shortages and changing consumer behavior led to a negative trajectory, prompting Rite Aid to file for Chapter 11 protection again [7].
Rite Aid Files for Bankruptcy, Job Cuts Expected
PYMNTS.com· 2025-05-05 23:28
Core Viewpoint - Rite Aid Corp. has filed for Chapter 11 bankruptcy protection for the second time in less than a year, indicating ongoing financial struggles despite previous restructuring efforts [1][3]. Group 1: Bankruptcy Filing - The recent bankruptcy filing marks Rite Aid's second in under three years, following an initial Chapter 11 filing in October 2023 aimed at reducing approximately $2 billion in debt [1]. - The previous restructuring involved closing around 850 store locations and resulted in lenders taking control of the business [1]. Group 2: Financial Position and Challenges - After emerging from bankruptcy in September 2023, Rite Aid claimed to be in a stronger position with significantly less debt and additional financial resources [2]. - However, the company still carries over $2 billion in debt and continues to face challenges from inflation and lower consumer demand [3]. Group 3: Strategic Actions - Rite Aid is pursuing a strategic and value-maximizing sale process for substantially all of its assets [3]. - The company plans to reduce its workforce at its corporate headquarters due to a dramatic downturn in the economy and increased expenses related to tariffs, suppliers, and landlords [3]. Group 4: Store Operations and Vendor Relations - Every Rite Aid store is expected to either cease operations or be sold, with discussions ongoing with various regional and national parties interested in acquiring portions of the business [4]. - A major vendor has informed Rite Aid of stricter and shorter payment terms, which could potentially trigger an acceleration of a company loan [4]. Group 5: Broader Retail Sector Concerns - Lenders across the retail sector are increasingly concerned about the future impact of tariffs, affecting not only retailers but also their technology partners [5]. - Venture capital for retail FinTechs has reportedly plummeted by 38% in the first quarter, reflecting broader financial anxieties in the retail industry [5].